Greenlight Capital Re to Release Third Quarter 2016 Results
Oct 24, 2016 12:32 pm UTC| Business
GRAND CAYMAN, Cayman Islands, Oct. 24, 2016 -- Greenlight Capital Re, Ltd. (NASDAQ:GLRE), a specialist property and casualty reinsurer based in the Cayman Islands and Ireland, today announced that it expects to release...
Greenlight Capital Re to Release Third Quarter 2016 Results
Oct 24, 2016 12:32 pm UTC| Business
GRAND CAYMAN, Cayman Islands, Oct. 24, 2016 -- Greenlight Capital Re, Ltd. (NASDAQ:GLRE), a specialist property and casualty reinsurer based in the Cayman Islands and Ireland, today announced that it expects to release...
Progenics Pharmaceuticals Sets Third Quarter 2016 Financial Results Call for November 7
Oct 24, 2016 12:32 pm UTC| Business
NEW YORK, Oct. 24, 2016 -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, announced today that it will host a...
Progenics Pharmaceuticals Sets Third Quarter 2016 Financial Results Call for November 7
Oct 24, 2016 12:32 pm UTC| Business
NEW YORK, Oct. 24, 2016 -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, announced today that it will host a...
Progenics Pharmaceuticals Sets Third Quarter 2016 Financial Results Call for November 7
Oct 24, 2016 12:32 pm UTC| Business
NEW YORK, Oct. 24, 2016 -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, announced today that it will host a...
Oct 24, 2016 12:32 pm UTC| Business
MADISON, Wis., Oct. 24, 2016 -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announces that it will be presenting data from its Phase 1...
Oct 24, 2016 12:32 pm UTC| Business
MADISON, Wis., Oct. 24, 2016 -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announces that it will be presenting data from its Phase 1...